Combo therapies tested to overcome drug resistance in melanoma patients
Tuesday, August 2, 2011 - 08:30
in Health & Medicine
About 50 to 60 percent of patients with melanoma have a mutation in the BRAF gene that drives the growth of their cancer. Most of these patients respond well to two novel agents being studied in clinical trials that inhibit the gene, with remarkable responses that are, unfortunately, almost always limited in duration.